FDA declines issue of EUA for COVAXIN pediatric vaccine

7 March 2022

USA-based Ocugen’s (Nasdaq: OCGN) shares were down 31% to $2.27, in premarket trading on Friday, as the company announced that the US Food and Drug Administration (FDA), at this time, has declined to issue an emergency use authorization (EUA) for COVAXIN (BBV152) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals two to 18 years of age.

Ocugen says it intends to continue working with the FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN.

The company is co-developing the Indian drugmaker Bharat Biotech originated COVAXIN vaccine candidate for COVID-19 in the USA and Canadian markets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK